305 related articles for article (PubMed ID: 32595208)
1. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
[TBL] [Abstract][Full Text] [Related]
2. Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
Gaible C; Narjoz C; Loriot MA; Roueff S; Pallet N
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1049-1053. PubMed ID: 34515833
[TBL] [Abstract][Full Text] [Related]
3. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
4. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
5. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
7. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
[TBL] [Abstract][Full Text] [Related]
8. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Arrivé C; Fonrose X; Thomas F; Roth G; Jacquet E; Brice A; Chirica C; Farneti D; Frenoux C; Stanke-Labesque F; Gautier-Veyret E
Br J Clin Pharmacol; 2023 Aug; 89(8):2446-2457. PubMed ID: 36918744
[TBL] [Abstract][Full Text] [Related]
9. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
10. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
[TBL] [Abstract][Full Text] [Related]
11. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
12. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
13. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives.
Narjoz C; Nadour Z; Zaanan A; Taieb J; Loriot MA; Pallet N
Clin Chim Acta; 2023 Mar; 543():117326. PubMed ID: 37011867
[TBL] [Abstract][Full Text] [Related]
14. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.
Saarenheimo J; Wahid N; Eigeliene N; Ravi R; Salomons GS; Ojeda MF; Vijzelaar R; Jekunen A; van Kuilenburg ABP
Cancer Chemother Pharmacol; 2021 May; 87(5):657-663. PubMed ID: 33544210
[TBL] [Abstract][Full Text] [Related]
15. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
[TBL] [Abstract][Full Text] [Related]
16. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
[TBL] [Abstract][Full Text] [Related]
17. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
18. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
Nguyen DG; Morris SA; Chen A; Moore DC; Hanson SL; Larck C; Musselwhite LW; Turner JD; Salem ME; Kwange SO; Hamilton A; Steuerwald N; Patel JN
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754463
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
20. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M; Launay M; Royer B; Guitton J; Gautier-Veyret E; Broutin S; Tron C; Le Louedec F; Ciccolini J; Richard D; Alarcan H; Haufroid V; Tafzi N; Schmitt A; Etienne-Grimaldi MC; Narjoz C; Thomas F;
Br J Clin Pharmacol; 2023 Feb; 89(2):762-772. PubMed ID: 36104927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
